Sarepta Therapeutics CSO Gilmore MMSc receives $6.4M in 2018

Sarepta Therapeutics reports 2018 executive compensation

By ExecPay News

Published: April 26, 2019

Sarepta Therapeutics reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, five executives at Sarepta Therapeutics received on average a compensation package of $3.7M, a 64% decrease compared to previous year.
Average pay of disclosed executives at Sarepta Therapeutics
Gilmore O'Neill, M.B., M.M.Sc, Chief Scientific Officer, received $6.4M in total. 73.93% of MMSc's compensation, or $4.8M, was in option awards. MMSc also received $213.4K in non-equity incentive plan, $311K in salary, $1.2M in stock awards, as well as $2.1K in other compensation.
For fiscal year 2018, the median employee pay was $329,229 at Sarepta Therapeutics. Therefore, the ratio of Gilmore O'Neill, M.B., M.M.Sc's pay to the median employee pay was 20 to one.
Sandesh Mahatme, Chief Financial Officer, received a compensation package of $4.2M, which increased by 92% compared to previous year. 79.64% of the compensation package, or $3.4M, was in option awards.
David Tyronne Howton, Jr, General Counsel, earned $3.1M in 2018, a 72% increase compared to previous year.
Alexander Cumbo, Executive Vice President, Chief Commercial Officer, received $3.1M in 2018, which increases by 34% compared to 2017.
Douglas Ingram, Chief Executive Officer, earned $1.4M in 2018, a 97% decrease compared to previous year.

Related executives

Douglas Ingram

Sarepta Therapeutics

Chief Executive Officer

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

David Howton

Sarepta Therapeutics

General Counsel

Gilmore MMSc

Sarepta Therapeutics

Chief Scientific Officer

Alexander Cumbo

Sarepta Therapeutics

Executive Vice President, Chief Commercial Officer

You may also like

Source: SEC filing on April 26, 2019.